Abstract

Study design: Observational digital survey.
Purpose: To assess the clinical experience of retina specialists (RS, N=58) regarding the safety, efficacy, and satisfaction of Ranibizumab biosimilar 0.5 mg injection (Visumab, Cipla Ltd.).
Methods: A questionnaire-based observational digital survey.
Results: 71% of RS used Visumab in treatment-naïve patients with wet AMD and 41% of them used in wet AMD patients on follow-up who were initially on another biologic/biosimilar. 60% of patients reported objective improvement (improvement in one line) in best-corrected visual acuity after one month. No severe ADR was reported within 24-48 hours of using Visumab. 77.6% of RS preferred Visumab due to satisfactory efficacy, least side effects and affordability.
Conclusion: Based on real-life experience, the biosimilar Ranibizumab (Visumab) can be a safe, efficacious and cost-effective treatment option.